May 1, 2025 — Uniquity Bio is welcoming Bill Meury as the company’s chairman, effective May 1. Meury is a respected biotech leader with deep expertise in strategic planning, commercialization, and business development across a range of therapeutic areas, and is recognized throughout the industry for his guidance of biotech companies through significant, strategic growth. He most recently served as CEO of Anthos Therapeutics, which was acquired by Novartis in April. 

 

Prior to joining Anthos, Meury was President and CEO of Karuna Therapeutics, a neuroscience company, where he led the organization through a period of rapid expansion and oversaw its transition into a fully-integrated R&D and commercial organization before its acquisition by Bristol-Myers Squibb Company (BMS). Before that, he served as Executive Vice President and Chief Commercial Officer at Allergan and was a partner at Hildred Capital Management. 

 

Stephen Tullman has stepped down from the position of Executive Chairman but will continue to serve Uniquity as a member of its Board of Directors. As a co-founder of Uniquity, he leaves his mark on a company poised to continue its record of accomplishments and success moving forward.